Publication:
Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study

Simple item page
dc.contributor.authorSALMAN, ANDAƇ
dc.contributor.authorsSalman, Andac; Ergun, Tulin; Maria Gimenez-Arnau, Ana
dc.date.accessioned2022-03-14T09:18:58Z
dc.date.available2022-03-14T09:18:58Z
dc.date.issued2020-02-17
dc.description.abstractBackground: The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. Methods: A retrospective cohort study was done to evaluate the effectiveness and safety of omalizumab in real-life conditions. The patients with CSU treated with omalizumab between 2015 and 2018 were included. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT). Results: A total of 106 patients were included. A complete response (CR) (UAS7:0) and a well-controlled activity (WCA) (UAS7:1 to <6) were observed in 50 (47.2%) and 35 (33%) patients, respectively. The number of patients with an UCT score >= 12 was also significantly increased. Higher rates of CR/WCA were observed with omalizumab monotherapy compared to combination with antihistamines. The combination of dapsone, colchicine, and omalizumab provided additional benefit in a small group. Conclusion: Treatment with omalizumab provided a rapid and sustainable improvement in real-life settings. The use of omalizumab as monotherapy or combined with antihistamines does not show differences in the treatment response. The combination of omalizumab with immunomodulatory agents might be of benefit in selected cases.
dc.identifier.doi10.1080/09546634.2019.1589639
dc.identifier.eissn1471-1753
dc.identifier.issn0954-6634
dc.identifier.pubmed30821591
dc.identifier.urihttps://hdl.handle.net/11424/242953
dc.identifier.wosWOS:000508081000015
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofJOURNAL OF DERMATOLOGICAL TREATMENT
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChronic spontaneous urticaria
dc.subjectchronic urticaria
dc.subjectomalizumab
dc.subjectreal-life
dc.subjectINDUCIBLE URTICARIA
dc.subjectMANAGEMENT
dc.subjectDIAGNOSIS
dc.subjectTHERAPY
dc.subjectEPIDEMIOLOGY
dc.subjectRETREATMENT
dc.titleReal-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study
dc.typearticle
dspace.entity.typePublication
local.avesis.idafc1b93c-78f9-49a4-a852-8e74dd156800
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
local.journal.quartileQ2
oaire.citation.endPage209
oaire.citation.issue2
oaire.citation.startPage204
oaire.citation.titleJOURNAL OF DERMATOLOGICAL TREATMENT
oaire.citation.volume31
relation.isAuthorOfPublication22ba329a-4b06-4eb1-8549-b8b32f2d766b
relation.isAuthorOfPublication.latestForDiscovery22ba329a-4b06-4eb1-8549-b8b32f2d766b

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Salman et al. - 2020 - Real-life data on the effectiveness and safety of .pdf
Size:
332.96 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs